Adopting a moderate risk posture, health authorities are proceeding with broader clinical integration of semaglutide and tirzepatide, backed by stringent post-marketing surveillance and targeted translational studies. While evidence highlights significant metabolic and cardiovascular benefits, ongoing safety signals necessitate vigilant monitoring for adverse effects like hair shedding and acute pancreatitis. Meanwhile, advancements in nephrology bolster the case for these therapies, but researchers remain skeptical about bridging preclinical successes to real-world clinical outcomes.